Study of an oral drug for venous, lymphatic, and certain overgrowth syndromes
Part of Blood & lymphatic, Genetic & congenital, Heart & circulation clinical trials.
This trial tests whether the study drug KP-001 can help reduce symptoms like pain, fatigue, or bleeding caused by certain vascular malformations (abnormal blood vessel growths) that can't be surgically removed or haven't responded to other treatments. It's for people age 2 and older with specific conditions such as common venous malformations, lymphatic malformations, or KTS/CLOVES syndrome.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 2 years or older
- You have been diagnosed with a common venous malformation, lymphatic malformation, or KTS/CLOVES syndrome that cannot be surgically removed or has not responded to available treatments
- You have at least one target lesion (abnormal growth) that is at least 4 cm in its longest measurement
- You have symptoms from the malformation, such as pain, fatigue, or bleeding/oozing (with specific pain or symptom scores depending on age)
- Your pain from the malformation has been stable for the past month, and you have not needed to change pain medications during that time
- You are willing to use effective birth control (if applicable) during the study and for 90 days after the last dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, RLY-2608, that targets the specific genetic change (PIK3CA mutation) causing overgrowth conditions. It aims to see if the drug can slow or stop the growth of affected tissues.
This study enrolls people with certain lymphatic (lymph fluid) conditions to collect information and track how they do over time. It may help doctors better understand outcomes and improve care.
This study collects extra blood (and sometimes tissue during procedures) to look for markers that can help doctors better understand vascular anomalies. It may not be a treatment, but it can improve future care by finding patterns linked to the condition.
This trial tests whether adding aspirin to standard care can reduce the number of painful blood clots in children with a specific vein condition. It may help lower the frequency of these episodes and improve quality of life.
This study tests whether new imaging techniques (called MSOT and ULM) can better see vascular malformations. It may help doctors diagnose and understand these conditions without the need for risky procedures.
This trial tests a new medication, KM-023, first in healthy volunteers to check safety, and then in people with Olmsted syndrome (a rare skin condition causing thick, painful palms and soles). It aims to see if the drug is safe and helpful for those affected.
Hear when a new Klippel Trenaunay Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.